AdjuTec Pharma, Venus Remedies Partner to Evaluate APC-148 for AMR

AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, announces that it has entered into a research collaboration agreement with Venus Remedies Limited (India).  The company will perform a pre-clinical evaluation of AdjuTec Pharma´s APC-148 platform technology.
 
AdjuTec Pharma has developed novel inhibitor technologies that selectively destroy antibiotic resistance mechanisms in multidrug-resistant bacteria, thereby restoring the effectiveness of commercially available antibiotics. APC-148 is the lead programme that is presently in phase 1 clinical trials. As a frontrunner in AMR, Venus will leverage its advanced R&D capabilities to assess APC-148’s potential in restoring the effectiveness of antibiotics against multidrug-resistant bacterial strains.
 
As part of this engagement, Venus will test APC-148 in combination with various antibiotics against its extensive library of clinical isolates collected through the GASAR study. The study forms part of Venus Remedies’ broader commitment to combating AMR and contributing to the UN’s ‘One Health’ objective.
 
AdjuTec Pharma and Venus Remedies Limited share a joint mission to address the global health threat against AMR. APC-148 has the potential to significantly restore the effectiveness of antibiotics against resistant bacterial strains that are increasingly burdening the Indian healthcare system.
 
Jethro Holter, CEO, AdjuTec Pharma AS, said: “This agreement perfectly aligns with our strategy to collaborate with leading and international pharmaceutical partners to address the most clinically challenging resistant pathogens through our groundbreaking technology.”
 
Saransh Chaudhary, president, Global critical care, Venus Remedies, and CEO, Venus Medicine Research Centre said: “This research engagement allows us to contribute our expertise in AMR toward advancing scientific understanding of novel solutions in this space. Our collaboration reflects a shared commitment to addressing the global AMR challenge through rigorous, innovation-driven research.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!